Mecasermin is recombinant human IGF-1; it is the only treatment for severe primary IGF-1 deficiency (growth hormone insensitivity), approved in the United States in 2005 and in Europe in 2007.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
Mecasermin is recombinant human IGF-1; it is the only treatment for severe primary IGF-1 deficiency (growth hormone insensitivity), approved in the United States in 2005 and in Europe in 2007. · pmid:19707272
In a phase 1 study in 12 girls with MECP2 mutations (9 with Rett syndrome), mecasermin reached the cerebrospinal fluid without hypoglycemia or serious adverse events, and apnea and some mood and anxiety measures improved in the open-label extension. · pmid:24623853
Identity
No public registry record is shown for this page: PubChem gave no record that proves it is this substance.
Where the evidence actually sits
Established50%
Emerging50%
Proportion of the 2 claims about IGF-1 (Mecasermin / recombinant human IGF-1) standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for IGF-1 (Mecasermin / recombinant human IGF-1) yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. · pmid 19707272 · 2009
Observational evidence· resolved human data at the emerging tier: thin, or contested
Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. · pmid 24623853 · 2014
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.